BioMarin Pharmaceutical (BMRN) Stock Surges on Strong Q4 Results and 2025 Guidance

BioMarin Pharmaceutical (BMRN) stock is trading up today, following the company's release of strong fourth-quarter results and positive guidance for 2025. The biopharmaceutical company, which focuses on rare disease therapies, reported adjusted EPS of $0.92, surpassing the $0.53 consensus, and sales of $747.31 million, beating the consensus of $713.44 million. Total revenues increased 16% year over year, driven by Voxzogo contributions from new patient starts in all regions.